| Literature DB >> 29109681 |
Jacqueline Reinhard1, Lars Roll1, Andreas Faissner1.
Abstract
Tenascins represent key constituents of the extracellular matrix (ECM) with major impact on central nervous system (CNS) development. In this regard, several studies indicate that they play a crucial role in axonal growth and guidance, synaptogenesis and boundary formation. These functions are not only important during development, but also for regeneration under several pathological conditions. Additionally, tenascin-C (Tnc) represents a key modulator of the immune system and inflammatory processes. In the present review article, we focus on the function of Tnc and tenascin-R (Tnr) in the diseased CNS, specifically after retinal and optic nerve damage and degeneration. We summarize the current view on both tenascins in diseases such as glaucoma, retinal ischemia, age-related macular degeneration (AMD) or diabetic retinopathy. In this context, we discuss their expression profile, possible functional relevance, remodeling of the interacting matrisome and tenascin receptors, especially under pathological conditions.Entities:
Keywords: extracellular matrix; glaucoma; glycoprotein; neurodegeneration; optic nerve; retina; tenascin-C; tenascin-R
Year: 2017 PMID: 29109681 PMCID: PMC5660115 DOI: 10.3389/fnint.2017.00030
Source DB: PubMed Journal: Front Integr Neurosci ISSN: 1662-5145
Figure 1Modular assembly of human tenascin-C (TNC) and tenascin-R (TNR) monomers. (A) In human, each TNC monomer consists of an amino-terminal tenascin assembly (TA) domain, a cysteine-rich domain, 14.5 epidermal-growth factor (EGF)-like domains, eight constitutive fibronectin (FN)-type III homologous domains and a fibrinogen (FG)-like carboxy-terminal part. Between the FN-type III domains 5 and 6, TNC can carry the additional FN-type III domains A1, A2, A3, A4, B, AD2, AD1, C and D due to alternative splicing. (B) Human TNR also consists of a TA domain and a cysteine-rich domain, in this case followed by 4.5 EGF-like domains, eight constitutive FN-type III domains and a FG-like carboxy-terminal part. The alternatively spliced FN-type III domain R can be inserted between the FN-type III domains 5 and 6. Abbreviations: EGF, epidermal-growth factor-like domain; FG, fibrinogen-like domain; FNIII, fibronectin-type III homologous domain; TA, amino-terminal tenascin assembly domain; TNC, human tenascin-C; TNR, human tenascin-R.
Figure 2Cartoon summarizing the current view on the expression of tenascins in the retina, optic nerve and iridocorneal angle. (A) Scheme of the adult human eye. (B) Scheme of the retina, optic nerve and iridocorneal angle. (C) Visualization of Tnc- and Tnr-expressing cell types/structures in the retina, optic nerve and iridocorneal angel. In the retina, horizontal, amacrine and displaced amacrine cells are a main source of Tnc expression (orange). Horizontal cells also co-express large amounts of Tnr (blue). Additionally, signals of both proteins can be observed in the plexiform layers (orange/blue). In the optic nerve, astrocytes show a strong Tnc expression (orange). Tnr (blue) is highly expressed by optic nerve oligodendrocytes and localized at myelinated fibers and nodes of Ranvier. In the iridocorneal angle, the basement membrane underlying the inner wall of Schlemm’s canal contains Tnc protein (orange). Abbreviations: A, astrocyte; BM, basement membrane; C, cornea; CS, corneoscleral tissue; I, iris; ICA, iridocorneal angle; IPL, inner plexiform layer; JC, juxtacanalicular tissue; L, lens; NFL, nerve fiber layer; NR, node of Ranvier; O, oligodendrocyte; ON, optic nerve; ONH, optic nerve head; OPL, outer plexiform layer; R, retina; S, sclera; SC, Schlemm’s canal; TM, trabecular meshwork; Tnc, tenascin-C; Tnr, tenascin-R, UV, uveal tissue.
Summary of the current knowledge on the regulation of tenascin-C (Tnc) and tenascin-R (Tnr) expression in retinal and optic nerve degeneration and eye diseases.
| Type of degeneration/eye disease | References | |
|---|---|---|
| High levels in choroidal neovascular membranes of AMD patients | Nicolò et al. ( | |
| Upregulated in fibrovascular membranes in eyes of diabetic patients | Ishikawa et al. ( | |
| Upregulated in basement membranes of diabetic human eyes | To et al. ( | |
| Upregulation in intravitreal membranes of patients with proliferative traumatic, idiopathic vitreoretinopathy and proliferative diabetic retinopathy | Hagedorn et al. ( | |
| Upregulated in the retina and optic nerve of an autoimmune-glaucoma rat model | Reinehr et al. ( | |
| Upregulated in the ONH of an IOP-induced glaucoma rat model | Johnson et al. ( | |
| Upregulation of specific isoforms in mechanically stretched TM cells | Keller et al. ( | |
| Upregulated in the ONH of POAG patients | Pena et al. ( | |
| Downregulation of small isoforms in the retina of an ischemia/reperfusion rat model | Reinhard et al. ( | |
| Upregulated following optic nerve crush in the goldfish | Battisti et al. ( | |
| Upregulated after rat optic nerve transection | Ajemian et al. ( | |
| Upregulation of the large isoform in the retina in a rat ischemia/reperfusion model | Reinhard et al. ( | |
| Upregulated in the regenerating visual pathway of the lizard | Lang et al. ( | |
| Expression not altered in the optic nerve of mice following injury | Becker et al. ( | |
| Reduced expression levels in the optic nerve of the salamander | Becker et al. ( |
Abbreviations: AMD, age-related macular degeneration; ONH, optic nerve head; POAG, primary open-angle glaucoma; TM, trabecular meshwork; Tnc, tenascin-C; Tnr, tenascin-R.